ic9.gd2.car.il-15 t-cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 15, 2019 (NCT03721068)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Disialoganglioside GD2Immunity, passive
Disialoganglioside GD2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05620342 | Early Phase 1 (Phase 1) | Jan 15, 2023 | Bellicum Pharmaceuticals, University of North Carolina at Chapel Hill |
| NCT03721068 | Phase 1 | Jul 15, 2019 | University of North Carolina at Chapel Hill |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of North Carolina at Chapel Hill | Academic/Hospital | 2 | 2 | 1 | 2019 |
| Bellicum Pharmaceuticals | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1